Analysts have clear opinions on NK.
NantKwest, Inc. (NK) is followed by analysts on the street.
Joel Beatty from Citigroup rates it a Sell with a target of $0.8.
Similarly, null null of null null a null with a target of null.
The consensus on the street is null.
What does NantKwest, Inc.(NK) do ?
NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.
NantKwest, Inc. (NK) Insider Trades
Multiple company employees have indulged in significant insider trading. NantKwest, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):
Dir, Thomas John C : S – Sale(-$86,000) of NK in the trading session of 2019-12-13.
Dir Thomas John C : S – Sale(-$19,918) of NK in the trading session of 2019-12-12.
Dir Thomas John C : S – Sale(-$29,790) of NantKwest, Inc. in the trading session of 2019-09-05.
Looking for stocks just like NK?
Based on Wall Street analyst research, several stocks are similar to NK
– SRNE [Info can be found here: https://www.nasdaq.com/market-activity/stocks/SRNE ]
– CLLS [Info can be found here: https://www.nasdaq.com/market-activity/stocks/CLLS ]
– ADRO [Info can be found here: https://www.nasdaq.com/market-activity/stocks/ADRO ]